genXone

What genXone does

genXone is a privately held, for-profit company founded in 2016 and headquartered in Poznan, Poland. Its self-stated positioning — "co-creating science and medicine" to help businesses grow and improve quality of life — is suggestive of a life sciences, biotech, or biomedical-services orientation, but the company's primary web presence (genxone.eu) returns only a verification/loading screen, so operational specifics cannot be independently verified. Public disclosure is limited to a website URL, a short tagline, the city/country of incorporation, and a single named executive (CEO Michał Kaszuba).

The company's commercial footprint is highly opaque in available sources: no products or services, no pricing model, no customers, no partnerships, no awards, no patents, no certifications, no integrations, and no product launches are listed. The only documented capital event is an early-stage funding round on 2020-04-16 of approximately $992,558 from Nunatak Capital, in what appears to be a seed/early-stage transaction. A financial table included in the aggregated source (showing revenue in the hundreds of billions to trillions of dollars and negative operating income) is internally inconsistent with a 2016 Polish firm that has raised under $1M in known capital and is treated as an unverified data artifact rather than evidence of scale.

Taken together, genXone presents as an early-stage, data-sparse private entity whose value proposition in science-and-medicine R&D or services is plausible on the basis of its tagline but unverifiable from current sources. Investment diligence would require direct access to management for clarification of product surface, customer pipeline, revenue model, and any intellectual-property or AI/ML assets underlying its stated mission.

Name

genXone

Website

https://genxone.eu

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

genXone is a privately held Polish company founded in 2016 that describes its mission as co-creating science and medicine to help businesses grow and improve quality of life. Specific products, customers, and revenue mechanics are undisclosed in available sources.

Ownership category

akta.pro rank

Headquarters

HQ city

Poznan

HQ country

Poland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

genXone co-creates science and medicine, helping businesses grow and improve quality of life through genomic, molecular, and life-science research services. The firm supports organizations in biotechnology, pharmaceutical, agricultural, and healthcare-adjacent sectors with applied genetics and biomedical capabilities.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Emerging players

• Fulgent Genetics: Fulgent Genetics is a US-based clinical and research genomics services company with growing international reach. It is a relevant emerging comparator for a clinical genomics services operator in Europe.
• Personalis: Personalis is a US-based genomics company focused on immuno-oncology and clinical-grade sequencing services. It is an emerging comparator for a small genomics services firm seeking pharma and clinical research customers.

Direct peers

• Centogene: Centogene is a Germany-headquartered rare-disease and genomics diagnostics company serving clinical and pharma customers. It is a close comparable for a European lab offering molecular diagnostics and translational genomics services.
• Eurofins Genomics: Eurofins Genomics is one of Europe's largest providers of genomic sequencing, genotyping, and molecular biology services. It is the most direct benchmark for a small Central European lab-services competitor pursuing pharma, academic, and clinical customers.
• Genewiz (Azenta Life Sciences): Genewiz, now part of Azenta, provides Sanger, NGS, and synthetic biology services globally. It is a direct competitor in the academic and pharma genomics-services market that genXone appears to target.
• Macrogen: Macrogen is a global DNA sequencing and genomics services provider with strong presence in Europe and Asia. It competes with genXone for outsourced NGS, Sanger sequencing, and clinical genomics projects.

Broad incumbents

• BGI Group: BGI and its subsidiaries (MGI, BGI Genomics) operate one of the world's largest sequencing service networks, including European operations. It competes for the same large-scale sequencing and population genomics opportunities.
• QIAGEN: QIAGEN is a global sample-prep, molecular diagnostics, and bioinformatics provider with deep European roots. Its molecular diagnostics and life-science research products overlap with the workflows genXone would deliver for customers.
• Eurofins Materiaux: Parent organization of Eurofins Genomics and one of the largest life-sciences testing groups worldwide. Its broad portfolio of bioanalytical services overlaps with the molecular diagnostics and genomics workflow that genXone provides.
• Illumina: Illumina is the dominant NGS platform vendor and also operates clinical and consortium genomics services. Although primarily a technology provider, its services and CLIA-certified labs compete for genomics workflow ownership across Europe.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/genxone

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about genXone